New drug combo aims to tame AML in patients too frail for strong chemo
NCT ID NCT03513484
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 1 trial tests the combination of nintedanib and azacitidine in older adults with acute myeloid leukemia (AML) who are not candidates for intensive chemotherapy. The goal is to find the safest dose of nintedanib when given with azacitidine and to see how well patients tolerate the combination. Up to 44 participants will receive treatment for up to 6 cycles, with the option to continue if it helps.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- nintedanib and azacitidine
- What this could lead to
- If it works, this could lead to a new treatment option for older AML patients who cannot tolerate intensive chemotherapy.
- What could go wrong
- This is an early phase 1 trial with only 44 participants, focused on safety and dosing. The combination may not be effective or could cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA WITH T(9;11)(P22.3;Q23.3); MLLT3-KMT2A are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Precision radiation may boost stem cell transplant success in tough leukemias
- Could a targeted drug keep AML in check?
- New drug aims to wake up immune system against Hard-to-Treat leukemia
- New drug combo aims to outsmart resistant leukemia
- Gentler chemo approach shows promise for tough blood cancers in older patients
- Experimental combo for resistant leukemia shows early promise but trial halted